STOCK Tg(MMTV-Erbb2)1Pv/Cnrm
| Status | Under development - register interest |
| EMMA ID | EM:13147 |
| Citation information | RRID:IMSR_EM:13147 Research Resource Identifiers (RRID) are persistent unique ID numbers assigned to help researchers cite key resources (e.g. antibodies, model organisms and software projects) in the biomedical literature to improve transparency and reproducibility in research. See https://www.rrids.org/ for more information. |
| International strain name | STOCK Tg(MMTV-Erbb2)1Pv/Cnrm |
| Alternative name | neuT |
| Strain type | Transgenic Strains |
| Allele/Transgene symbol | Tg(MMTV-Erbb2)1Pv |
| Gene/Transgene symbol | Tg(MMTV-Erbb2)1Pv |
Information from provider
| Provider | Eleonora Aricò |
| Provider affiliation | Core Facilities Technical-Scientific Service, Istituto Superiore di Sanità |
| Genetic information | Mice are heterozygous for the mutated rat Erbb2 (Her2/neu) oncogene driven by the MMTV promoter. |
| Phenotypic information | Homozygous:The generation of mice homozygous for the activated rat Erbb2 (Her2/neu) transgene has not been reported, probably due to embryonic lethality.Heterozygous:Mice carrying the heterozygous activated rat Erbb2 (Her2/neu) transgene are viable. Female are fertile but usually do not breastfeed their progeny. Male are fertile. Mice transgenic for rat Her2/neu spontaneously develop mammary carcinoma (female) and salivary gland carcinoma (male). |
| Breeding history | neuT mice were generated at the animal facility of the Istituto Superiore di Sanità (Rome, Italy) by performing 12 backcrosses of BALB-neuT transgenic males (kindly provided by Dr. Guido Forni) with 129Sv females (originally purchased from Charles River). The BALB-neuT strain (Cancer Lett., 1992;64:203-9 - PMID: 1322235), originated from a transgenic CD1 random-bred breeder male mouse (no. 1330) carrying the mutated rat HER-2/neu oncogene driven by the MMTV promoter (Muller et al., Cell 1988). |
| References |
|
| Homozygous fertile | no |
| Homozygous viable | no |
| Homozygous matings required | no |
| Immunocompromised | no |
Information from EMMA
| Archiving centre | CNR, Consiglio Nazionale delle Ricerche, Monterotondo, Italy |
| Breeding at archiving centre | 1 backcross to C57BL/6N |
Literature references
- Disruption of IFN-I Signaling Promotes HER2/Neu Tumor Progression and Breast Cancer Stem Cells.;Castiello Luciano, Sestili Paola, Schiavoni Giovanna, Dattilo Rosanna, Monque Domenica M, Ciaffoni Fiorella, Iezzi Manuela, Lamolinara Alessia, Sistigu Antonella, Moschella Federica, Pacca Anna Maria, Macchia Daniele, Ferrantini Maria, Zeuner Ann, Biffoni Mauro, Proietti Enrico, Belardelli Filippo, Aricò Eleonora, ;2018;Cancer immunology research;6;658-670; 29622580
- Engineered exosomes emerging from muscle cells break immune tolerance to HER2 in transgenic mice and induce antigen-specific CTLs upon challenge by human dendritic cells.;Anticoli Simona, Aricò Eleonora, Arenaccio Claudia, Manfredi Francesco, Chiozzini Chiara, Olivetta Eleonora, Ferrantelli Flavia, Lattanzi Laura, D'Urso Maria Teresa, Proietti Enrico, Federico Maurizio, ;2018;Journal of molecular medicine (Berlin, Germany);96;211-221; 29282521
- Chemo-immunotherapy induces tumor regression in a mouse model of spontaneous mammary carcinogenesis.;Aricò Eleonora, Sestili Paola, Carpinelli Giulia, Canese Rossella, Cecchetti Serena, Schiavoni Giovanna, D'Urso Maria Teresa, Belardelli Filippo, Proietti Enrico, ;2016;Oncotarget;7;59754-59765; 27486759
- Type I IFNs promote cancer cell stemness by triggering the epigenetic regulator KDM1B.;Musella Martina, Guarracino Andrea, Manduca Nicoletta, Galassi Claudia, Ruggiero Eliana, Potenza Alessia, Maccafeo Ester, Manic Gwenola, Mattiello Luca, Soliman Abdel Rehim Sara, Signore Michele, Pietrosanto Marco, Helmer-Citterich Manuela, Pallocca Matteo, Fanciulli Maurizio, Bruno Tiziana, De Nicola Francesca, Corleone Giacomo, Di Benedetto Anna, Ercolani Cristiana, Pescarmona Edoardo, Pizzuti Laura, Guidi Francesco, Sperati Francesca, Vitale Sara, Macchia Daniele, Spada Massimo, Schiavoni Giovanna, Mattei Fabrizio, De Ninno Adele, Businaro Luca, Lucarini Valeria, Bracci Laura, Aricò Eleonora, Ziccheddu Giovanna, Facchiano Francesco, Rossi Stefania, Sanchez Massimo, Boe Alessandra, Biffoni Mauro, De Maria Ruggero, Vitale Ilio, Sistigu Antonella, ;2022;Nature immunology;23;1379-1392; 36002648
- A nanoencapsulated oral formulation of fenretinide promotes local and metastatic breast cancer dormancy in HER2/neu transgenic mice.;De Angelis Maria Laura, Francescangeli Federica, Aricò Eleonora, Verachi Paola, Zucchetti Massimo, Matteo Cristina, Petricci Elena, Pilozzi Emanuela, Orienti Isabella, Boe Alessandra, Eramo Adriana, Rossi Rachele, Corati Tiberio, Macchia Daniele, Pacca Anna Maria, Zeuner Ann, Baiocchi Marta, ;2024;Journal of experimental & clinical cancer research : CR;43;296; 39497135
- Anticancer Effects of Sublingual Type I IFN in Combination with Chemotherapy in Implantable and Spontaneous Tumor Models.;Ciccolella Maria, Andreone Sara, Mancini Jacopo, Sestili Paola, Negri Donatella, Pacca Anna Maria, D'Urso Maria Teresa, Macchia Daniele, Canese Rossella, Pang Ken, SaiYing Ko Thomas, Decadt Yves, Schiavoni Giovanna, Mattei Fabrizio, Belardelli Filippo, Aricò Eleonora, Bracci Laura, ;2021;Cells;10;; 33917958